Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Certification | 2 | 2017 | 24 | 0.630 |
Why?
|
| Pancreas Transplantation | 7 | 2021 | 17 | 0.610 |
Why?
|
| General Surgery | 2 | 2017 | 49 | 0.610 |
Why?
|
| Test Taking Skills | 1 | 2017 | 2 | 0.520 |
Why?
|
| Internship and Residency | 2 | 2017 | 197 | 0.510 |
Why?
|
| Clinical Competence | 1 | 2017 | 189 | 0.450 |
Why?
|
| Kidney Transplantation | 4 | 2021 | 113 | 0.380 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 22 | 0.340 |
Why?
|
| Organ Transplantation | 4 | 2021 | 32 | 0.330 |
Why?
|
| Liver Transplantation | 4 | 2014 | 81 | 0.310 |
Why?
|
| Tissue and Organ Procurement | 4 | 2009 | 31 | 0.240 |
Why?
|
| Educational Measurement | 2 | 2017 | 53 | 0.240 |
Why?
|
| Graft Rejection | 4 | 2009 | 64 | 0.230 |
Why?
|
| Aneurysm | 1 | 2022 | 10 | 0.180 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 10 | 0.180 |
Why?
|
| Adult | 15 | 2020 | 6959 | 0.180 |
Why?
|
| Renal Dialysis | 3 | 2022 | 82 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 12 | 0.180 |
Why?
|
| Graft Survival | 6 | 2014 | 84 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 53 | 0.170 |
Why?
|
| Surgical Instruments | 1 | 2020 | 24 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2020 | 61 | 0.160 |
Why?
|
| Suture Techniques | 1 | 2020 | 112 | 0.160 |
Why?
|
| Humans | 22 | 2022 | 23187 | 0.160 |
Why?
|
| Male | 16 | 2020 | 12659 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2022 | 2993 | 0.140 |
Why?
|
| Female | 15 | 2020 | 13142 | 0.140 |
Why?
|
| Treatment Outcome | 10 | 2022 | 2943 | 0.140 |
Why?
|
| Intestines | 2 | 2008 | 77 | 0.140 |
Why?
|
| United States | 4 | 2017 | 1803 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 103 | 0.130 |
Why?
|
| Simulation Training | 1 | 2017 | 34 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 67 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 123 | 0.120 |
Why?
|
| Curriculum | 1 | 2017 | 124 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2017 | 128 | 0.120 |
Why?
|
| Time Factors | 5 | 2022 | 1264 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Middle Aged | 13 | 2020 | 7981 | 0.110 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 2 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 121 | 0.100 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 14 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 13 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 20 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 34 | 0.100 |
Why?
|
| Stents | 1 | 2013 | 75 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 198 | 0.090 |
Why?
|
| Liver | 2 | 2009 | 135 | 0.090 |
Why?
|
| Vascular Patency | 2 | 2022 | 17 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 113 | 0.090 |
Why?
|
| Child | 6 | 2009 | 1160 | 0.090 |
Why?
|
| Stomach | 1 | 2009 | 14 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 23 | 0.080 |
Why?
|
| Aged | 9 | 2020 | 7660 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2009 | 17 | 0.070 |
Why?
|
| Leucine | 1 | 2009 | 11 | 0.070 |
Why?
|
| Gastric Fistula | 1 | 2009 | 5 | 0.070 |
Why?
|
| Intestinal Fistula | 1 | 2009 | 4 | 0.070 |
Why?
|
| Colonic Diseases | 1 | 2009 | 7 | 0.070 |
Why?
|
| Living Donors | 1 | 2009 | 16 | 0.070 |
Why?
|
| Hypoglycemia | 1 | 2009 | 12 | 0.070 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2008 | 4 | 0.070 |
Why?
|
| Colon | 1 | 2009 | 112 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 11 | 0.070 |
Why?
|
| Organ Preservation Solutions | 1 | 2008 | 1 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2008 | 23 | 0.070 |
Why?
|
| Pancreatectomy | 1 | 2008 | 11 | 0.070 |
Why?
|
| Program Development | 1 | 2008 | 44 | 0.070 |
Why?
|
| Menorrhagia | 1 | 2008 | 2 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2008 | 25 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 8 | 0.070 |
Why?
|
| Lung Transplantation | 1 | 2007 | 6 | 0.070 |
Why?
|
| Adolescent | 5 | 2009 | 1884 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 107 | 0.060 |
Why?
|
| Tissue Donors | 2 | 2021 | 67 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2008 | 185 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2009 | 168 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2002 | 88 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2014 | 226 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2009 | 569 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2002 | 10 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2002 | 34 | 0.050 |
Why?
|
| Waiting Lists | 2 | 2014 | 15 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 19 | 0.050 |
Why?
|
| Glucuronidase | 1 | 2002 | 9 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2002 | 23 | 0.050 |
Why?
|
| Risk Factors | 2 | 2022 | 2020 | 0.040 |
Why?
|
| Carcinoma | 1 | 2002 | 68 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 50 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 21 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 30 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 135 | 0.040 |
Why?
|
| Cost Savings | 1 | 2020 | 29 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 106 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 142 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 633 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2020 | 812 | 0.040 |
Why?
|
| Insulin | 2 | 2008 | 77 | 0.030 |
Why?
|
| Infant | 2 | 2008 | 483 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2009 | 3865 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 1430 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 377 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 134 | 0.030 |
Why?
|
| Young Adult | 2 | 2009 | 1657 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 310 | 0.020 |
Why?
|
| Reoperation | 2 | 2008 | 743 | 0.020 |
Why?
|
| Probability | 2 | 2002 | 72 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2013 | 382 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1037 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2002 | 353 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 27 | 0.020 |
Why?
|
| Prognosis | 2 | 2002 | 730 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 11 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2009 | 32 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 162 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2009 | 38 | 0.020 |
Why?
|
| Raffinose | 1 | 2008 | 1 | 0.020 |
Why?
|
| Allopurinol | 1 | 2008 | 3 | 0.020 |
Why?
|
| Procaine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2008 | 5 | 0.020 |
Why?
|
| Amylases | 1 | 2008 | 5 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 19 | 0.020 |
Why?
|
| Mannitol | 1 | 2008 | 11 | 0.020 |
Why?
|
| Lipase | 1 | 2008 | 4 | 0.020 |
Why?
|
| Adenosine | 1 | 2008 | 8 | 0.020 |
Why?
|
| Indiana | 1 | 2008 | 12 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 26 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 38 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 104 | 0.020 |
Why?
|
| Glucose | 1 | 2008 | 45 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 36 | 0.020 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cadaver | 1 | 2009 | 284 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 9 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2008 | 26 | 0.020 |
Why?
|
| Ureter | 1 | 2008 | 27 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 188 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 598 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 164 | 0.020 |
Why?
|
| Endoscopy | 1 | 2008 | 167 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 550 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 804 | 0.010 |
Why?
|
| Pancreatitis | 1 | 2002 | 20 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 28 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 19 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 49 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 30 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 77 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 88 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 228 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 180 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 288 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 320 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 442 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 445 | 0.010 |
Why?
|